Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Gross Margin (2016 - 2025)

Mimedx (MDXG) has disclosed Gross Margin for 15 consecutive years, with 83.86% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 206.0% to 83.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 82.56% through Dec 2025, down 22.0% year-over-year, with the annual reading at 82.56% for FY2025, 22.0% down from the prior year.
  • Gross Margin hit 83.86% in Q4 2025 for Mimedx, roughly flat from 83.54% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 86.03% in Q4 2021 to a low of 80.68% in Q4 2022.
  • Historically, Gross Margin has averaged 82.81% across 5 years, with a median of 82.82% in 2024.
  • Biggest five-year swings in Gross Margin: plummeted -535bps in 2022 and later soared 338bps in 2023.
  • Year by year, Gross Margin stood at 86.03% in 2021, then decreased by -6bps to 80.68% in 2022, then rose by 4bps to 84.06% in 2023, then dropped by -3bps to 81.8% in 2024, then rose by 3bps to 83.86% in 2025.
  • Business Quant data shows Gross Margin for MDXG at 83.86% in Q4 2025, 83.54% in Q3 2025, and 81.05% in Q2 2025.